5 Penny Stocks Insiders Buy

When insiders buy or sell stock, it indicates their confidence or concern about the company’s prospects. Investors and traders interested in penny stocks may consider it a factor in their overall investment or trading decision.

Below are some recent notable insider trades for penny stocks. For more, check out Benzinga’s Insider Trading platform.

Broad Street Realty

The trade: Broad Street Realty, Inc. (OTC: BRST) Director Samuel M Spiritos acquired a total of 10885 shares at an average price of $2.28. To acquire these shares, it cost $24,831.65.

What is going on: The company’s stock is up more than 30% in the past month.

What Broad Street Realty Does?: Broad Street Realty Inc. is a fully integrated real estate company that owns, operates, develops and redevelops primarily supermarket-based malls and street stores in the Mid-Atlantic and Denver, Colorado markets.

Baudax Organic

The trade: Baudax Bio, Inc. (NASDAQ: BXRX) Director Winston Churchill acquired a total of 100,000 shares shares at an average price of $0.63. The insider spent $62,930.00 to buy those shares.

What is going on: The company released dismal quarterly results last month.

What Baudax Bio does?: Baudax Bio Inc. is a pharmaceutical company. The company develops and commercializes products for hospitals and related acute care environments.

chalice

The trade: Calyxt, Inc. (NASDAQ: CLXT) President and CEO Michael A Carr acquired a total of 10,000 shares at an average price of $3.98. To acquire these shares, it cost $39,776.00.

What is going on: Calyxt reported better-than-expected quarterly results last month.

What Calyxt does?: Calyxt Inc is a technology company focused on delivering plant-based innovations and solutions.

ReShape Life Sciences

The trade: ReShape Life Sciences Inc. (NASDAQ: RSLS) Chief Financial Officer Thomas Stankovich acquired a total of 15,000 shares at an average price of $3.43. To acquire these shares, it cost $51,435.00.

What is going on: The company recently reported second-quarter revenue of $3.5 million, up from $1.7 million in the same period a year ago.

What ReShape Lifesciences does?: Reshape Lifesciences Inc. is a developer of minimally invasive medical devices for the treatment of obesity and metabolic diseases.

Amplify energy

The trade: Amplify Energy Corp. (NYSE: AMPY) Director Evan Lederman acquired a total of 10,000 shares at an average price of $3.69. To acquire these shares, it cost $36,900.00.

What is going on: The company reported a smaller quarterly loss last month.

What Amplify Energy does?: Amplify Energy Corp. is an independent oil and natural gas company engaged in the acquisition, development, operation and production of oil and natural gas properties in the United States.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.